Study: Ogawa M, et al. Changes in Sleep Quality after Hormone Replacement Therapy with Micronized Progesterone in Japanese Menopausal Women. J Menopausal Med. 2025 Apr. PMCID: PMC12070122
Key Findings:
A 2025 open-label study from Japan examined the effects of hormone replacement therapy (HRT) on sleep quality in peri- and postmenopausal women, focusing on the addition of oral micronized progesterone (MP). At baseline, 87% of the participants were classified as poor sleepers using the Pittsburgh Sleep Quality Index (PSQI).
After initiating combined HRT with estradiol and oral micronized progesterone:
- Significant improvements in sleep quality were reported at 1 month and continued through 3 months.
- Global PSQI scores improved across multiple domains, with the greatest benefit observed in women with the poorest initial sleep efficiency.
Why This Matters for Clinical Practice:
Micronized progesterone is more than a reproductive hormone—it functions as a neurosteroid, exerting sedative and anxiolytic effects via its metabolite allopregnanolone, which modulates GABA-A receptors in the brain. This study reinforces what many BHRT providers observe clinically: when appropriately prescribed, bioidentical progesterone
supports not only sleep initiation but deeper, restorative sleep.
While further research is warranted, especially in larger randomized trials, this study adds to the growing body of literature supporting bioidentical progesterone as a therapeutic tool for improving sleep and quality of life in menopausal women.
Clinical Takeaway:
For patients struggling with insomnia or poor sleep quality in menopause, consider evaluating progesterone status and trialing oral micronized progesterone, ideally dosed at bedtime (commonly 100–300 mg). Monitor improvements with validated tools like the PSQI and adjust the regimen based on response and tolerability.
